AU2023246859A1 - New treatment for facioscapulohumeral muscular dystrophy (fshd) - Google Patents

New treatment for facioscapulohumeral muscular dystrophy (fshd) Download PDF

Info

Publication number
AU2023246859A1
AU2023246859A1 AU2023246859A AU2023246859A AU2023246859A1 AU 2023246859 A1 AU2023246859 A1 AU 2023246859A1 AU 2023246859 A AU2023246859 A AU 2023246859A AU 2023246859 A AU2023246859 A AU 2023246859A AU 2023246859 A1 AU2023246859 A1 AU 2023246859A1
Authority
AU
Australia
Prior art keywords
myostatin
antibody
seq
set forth
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023246859A
Other languages
English (en)
Other versions
AU2023246859A9 (en
Inventor
Eleni GAKI
Tammy MCIVER
Renata SICILIANI SCALCO
Kathryn Rae Wagner
Wai Yin YEUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of AU2023246859A1 publication Critical patent/AU2023246859A1/en
Publication of AU2023246859A9 publication Critical patent/AU2023246859A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2023246859A 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd) Pending AU2023246859A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166261 2022-04-01
EP22166261.2 2022-04-01
PCT/EP2023/058218 WO2023187022A1 (en) 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd)

Publications (2)

Publication Number Publication Date
AU2023246859A1 true AU2023246859A1 (en) 2024-09-05
AU2023246859A9 AU2023246859A9 (en) 2024-09-12

Family

ID=81328333

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023246859A Pending AU2023246859A1 (en) 2022-04-01 2023-03-30 New treatment for facioscapulohumeral muscular dystrophy (fshd)

Country Status (11)

Country Link
US (1) US20250171526A1 (https=)
EP (1) EP4504779A1 (https=)
JP (1) JP2025511167A (https=)
KR (1) KR20240165959A (https=)
CN (1) CN119053619A (https=)
AU (1) AU2023246859A1 (https=)
CA (1) CA3255735A1 (https=)
IL (1) IL315473A (https=)
MX (1) MX2024011922A (https=)
TW (1) TW202346345A (https=)
WO (1) WO2023187022A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
AR107078A1 (es) 2015-12-18 2018-03-21 Chugai Pharmaceutical Co Ltd Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso

Also Published As

Publication number Publication date
TW202346345A (zh) 2023-12-01
AU2023246859A9 (en) 2024-09-12
EP4504779A1 (en) 2025-02-12
KR20240165959A (ko) 2024-11-25
JP2025511167A (ja) 2025-04-15
MX2024011922A (es) 2024-11-08
WO2023187022A1 (en) 2023-10-05
IL315473A (en) 2024-11-01
CN119053619A (zh) 2024-11-29
CA3255735A1 (en) 2023-10-05
US20250171526A1 (en) 2025-05-29

Similar Documents

Publication Publication Date Title
AU2020210134B2 (en) Use of myostatin inhibitors and combination therapies
US20240391989A1 (en) Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies
JP7003354B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
US12358993B2 (en) Methods for the treatment of thyroid eye disease
US20230365669A1 (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
US20240358704A1 (en) Combined administration
KR20220054608A (ko) ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
WO2023187022A1 (en) New treatment for facioscapulohumeral muscular dystrophy (fshd)
HK40112393A (zh) 用於面肩肱型肌营养不良症(fshd)的新治疗
HK40103690A (zh) 新颖的组合施用
WO2025106642A1 (en) Methods for the treatment of thyroid eye disease
WO2024129468A1 (en) Methods for the treatment of noninfectious uveitis

Legal Events

Date Code Title Description
SREP Specification republished